AR104528A1 - Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents
Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricasInfo
- Publication number
- AR104528A1 AR104528A1 ARP160101278A ARP160101278A AR104528A1 AR 104528 A1 AR104528 A1 AR 104528A1 AR P160101278 A ARP160101278 A AR P160101278A AR P160101278 A ARP160101278 A AR P160101278A AR 104528 A1 AR104528 A1 AR 104528A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylcarbonyl
- pyridinyl
- pyrimidinyl
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- -1 6-amino-2 sulfonimidoyl-9-substituted-7H-purin-8-one Chemical class 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud se refiere a compuestos derivados de 6-amino-2 sulfonimidoil-9-sustituido-7H-purin-8-ona, sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones con actividad agonista de receptores Toll. Reivindicación 1: Un compuesto de fórmula (1), en la que R¹ es alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquil C₃₋₇alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, o pirrolidinil-alquilo C₁₋₆; R² es alquilo C₁₋₆, fenil-alquilo C₁₋₆, piridinil-alquilo C₁₋₆ o pirimidinil-alquilo C₁₋₆, dicho fenil-alquilo C₁₋₆, piridinil-alquilo C₁₋₆ y pirimidinil-alquilo C₁₋₆ están sin sustituir o sustituidos por uno, dos o tres sustituyentes seleccionados independientemente entre halógeno, alquilo C₁₋₆, alcoxi C₁₋₆, ciano, carboxi, carbamoilo, haloalquilo C₁₋₆, alquilsulfonilo C₁₋₆, alcoxicarbonilo C₁₋₆, alcoxi C₁₋₆, alquilaminocarbonilo C₁₋₆, pirrolidinilcarbonilo y piperidinilcarbonilo; R³ es H; o una sal, enantiómero o diastereómero farmacéuticamente aceptable de los mismos. Reivindicación 19: Un compuesto de fórmula (2), en la que R⁴ es alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquil C₃₋₇alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆ o pirrolidinil-alquilo C₁₋₆; R⁵ es alquilo C₁₋₆, fenil-alquilo C₁₋₆, piridinil-alquilo C₁₋₆ o pirimidinil-alquilo C₁₋₆, dicho fenil-alquilo C₁₋₆, piridinil-alquilo C₁₋₆, y pirimidinil-alquilo C₁₋₆ están sin sustituir o sustituidos por uno, dos o tres sustituyentes seleccionados independientemente entre halógeno, alquilo C₁₋₆, alcoxi C₁₋₆, ciano, carboxi, carbamoilo, haloalquilo C₁₋₆, alquilsulfonilo C₁₋₆, alcoxicarbonilo C₁₋₆, alcoxi C₁₋₆, alquilaminocarbonilo C₁₋₆, pirrolidinilcarbonilo y piperidinilcarbonilo; R⁶ es H o alquil C₁₋₆-C(O)O-alquilo C₁₋₆-; R⁷ es H, alquilo C₁₋₆, cicloalquilo C₃₋₇ o alquilcarbonilo C₁₋₁₀; R⁸ es H, alquilcarbonilo C₁₋₆, carboxi-alquilcarbonilo C₁₋₆, alcoxicarbonilo C₁₋₆, alquilcarbonilo C₁₋₆ o benzoilo; con la condición de R⁶, R⁷ y R⁸ no sean H simultáneamente, o una sal, enantiómero o diastereómero farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015078507 | 2015-05-08 | ||
| CN2016078785 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104528A1 true AR104528A1 (es) | 2017-07-26 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101278A AR104528A1 (es) | 2015-05-08 | 2016-05-05 | Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9708325B2 (es) |
| EP (1) | EP3294740B1 (es) |
| JP (1) | JP6738352B2 (es) |
| KR (1) | KR102690131B1 (es) |
| CN (1) | CN107580596B (es) |
| AR (1) | AR104528A1 (es) |
| AU (3) | AU2016260683B2 (es) |
| BR (1) | BR112017023959B1 (es) |
| CA (1) | CA2982704C (es) |
| CL (1) | CL2017002745A1 (es) |
| CO (1) | CO2017009994A2 (es) |
| CR (1) | CR20170496A (es) |
| DK (1) | DK3294740T3 (es) |
| ES (1) | ES2753777T3 (es) |
| HR (1) | HRP20191942T1 (es) |
| HU (1) | HUE045906T2 (es) |
| IL (2) | IL254947B (es) |
| LT (1) | LT3294740T (es) |
| MX (2) | MX393198B (es) |
| MY (1) | MY182353A (es) |
| NZ (2) | NZ735648A (es) |
| PE (1) | PE20171620A1 (es) |
| PH (1) | PH12017502009A1 (es) |
| PL (1) | PL3294740T3 (es) |
| PT (1) | PT3294740T (es) |
| RS (1) | RS59435B1 (es) |
| RU (1) | RU2745269C2 (es) |
| SG (1) | SG10202108841YA (es) |
| SI (1) | SI3294740T1 (es) |
| TW (2) | TWI706954B (es) |
| UA (1) | UA120450C2 (es) |
| WO (1) | WO2016180695A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59435B1 (sr) * | 2015-05-08 | 2019-11-29 | Hoffmann La Roche | Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije |
| MA46038B1 (fr) * | 2016-08-29 | 2021-05-31 | Hoffmann La Roche | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale |
| BR112019004560A2 (pt) | 2016-09-13 | 2019-07-02 | Hoffmann La Roche | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| PE20211456A1 (es) * | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| CN119455003A (zh) * | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| CN114450280B (zh) | 2019-09-20 | 2025-02-25 | 先正达农作物保护股份公司 | 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132590A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| JP2025522978A (ja) | 2022-07-14 | 2025-07-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの処置のためのホスホリルプリノン化合物 |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| CN101203519A (zh) | 2005-05-04 | 2008-06-18 | 辉瑞有限公司 | 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2－酰氨基－6－氨基－8－氧代嘌呤衍生物 |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| TW201639852A (zh) * | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TW201636330A (zh) * | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| ES2690082T3 (es) | 2011-11-09 | 2018-11-19 | Janssen Sciences Ireland Uc | Derivados de purina para el tratamiento de infecciones virales |
| MX366481B (es) | 2013-03-29 | 2019-07-09 | Janssen Sciences Ireland Uc | Deaza-purinonas macrociclicas para el tratamiento de infecciones virales. |
| CN106661034B (zh) | 2014-08-15 | 2019-11-29 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| RS59435B1 (sr) * | 2015-05-08 | 2019-11-29 | Hoffmann La Roche | Nova jedinjenja sulfonimidoil purinona i njihovi derivati za lečenje i profilaksu virusne infekcije |
| MA46038B1 (fr) * | 2016-08-29 | 2021-05-31 | Hoffmann La Roche | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale |
-
2016
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt active IP Right Grant
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh active
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104528A1 (es) | Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092503A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR109665A1 (es) | Mezclas herbicidas | |
| ES2657549T3 (es) | Piridopirazinas sustituidas como nuevos inhibidores de SYK | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR101392A1 (es) | COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| AR102222A1 (es) | Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos | |
| PE20211456A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado | |
| AR101222A1 (es) | Derivados de piridona | |
| AR101155A1 (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
| AR091731A1 (es) | Antagonistas del receptor de mineralocorticoides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |